- Leadership Team is responsible for the design and development of business and investment strategies and, upon Board approval, the execution of strategies, administrative operations, and organizational growth of GHIT.
Catherine Kaseri Ohura is CEO & Executive Director of the GHIT Fund — Previously, she served as the Executive Officer and Unit Head of Japan Commercial Operations & Customer Experience at Bristol-Myers Squibb (BMS) K.K. (located in Japan). She also served as Executive Officer and Senior Director, Regional R&D Operations (responsible for Japan, China R&D Operations) at BMS K.K. At BMS (in the US), one of her roles was the Global Lead/General Manager for the BMS Network of Women (B-NOW). In this groundbreaking industry leadership role, she drove business performance at BMS globally by fostering a more powerfully diverse and broadly inclusive people and business strategy. Prior to her role at BMS, Ohura worked in Japanese pharmaceutical company for clinical development, regulatory affairs, quality assurance, pharmacovigilance, and project management. She received her undergraduate degree in chemistry, mathematics, and business from the University of Denver, and a master’s degree in regulatory affairs and quality assurance from Temple University School of Pharmacy. She has completed all but dissertation in the PhD program for Project Management at Capella University and is PMP (Project Management Professional) certified.
Kio Yamabe is Chief Operating Officer at the GHIT Fund, where he leads operations, human resources, legal and compliance, and also oversees finance and investment. Mr. Yamabe has more than 25 years of management experience in the pharmaceutical and healthcare industry, including as President and Country Manager of Carestream Health and CSL Behring. He has lived and worked in Australia, Switzerland, the United Kingdom, and the United States, including as Head of International Business at Fast Retailing Co., Ltd., where he led the launch of UNIQLO stores in London. He received his MBA from IMD in Switzerland and a BS from Seinan Gakuin University in Japan.
Daisuke Imoto currently serves as Vice President of External Affairs & Corporate Development at the GHIT Fund. Previously, he led the Japan office of Drugs for Neglected Diseases initiative (DNDi), not-for-profit R&D organization based in Geneva that is developing treatments for neglected patients. Daisuke also gained an experience in the pharmaceutical industry as public affairs professional at Eli Lilly. Prior to his role at Lilly, he worked in development with Japanese governmental agencies (JBIC and JICA) and worked and studied in France for more than 5 years. He received his MBA from INSEAD in France and a BS in Law from the University of Tokyo.
Kei Katsuno is Senior Director of Investment Strategy & Business Development at the GHIT Fund. Previously, he worked as a Health Specialist at the World Bank, following his completion of a fellowship at the Asia Pacific Leadership Program at the East West Center. Dr. Katsuno graduated from the University of Tokyo with a medical degree and worked as a medical doctor in the Emergency Medicine Department of the National Center for Global Health and Medicine (formerly International Medical Center of Japan). He possesses both Japanese and U.S. medical licenses (ECFMG) and completed the MPH program at the Johns Hopkins University as a Fulbright Scholar. He is a lecturer at the Department of Biomedical Chemistry, Graduate School of Medicine at the University of Tokyo, and a fellow of the U.S.-Japan Leadership Program.
Nozomi Nakade is Senior Manager of CEO Office at the GHIT Fund, where she provides strategic support for the CEO’s projects and engagements. Previously, she spent eight years at Bristol-Myers Squibb (BMS) Japan K.K., where she was Project Coordinator for the Commercial Operations & Customer Experience Unit, as well as Regional R&D Operations Unit, reporting directly to the Executive Officer/Unit Head. In these roles, she worked closely with the Executive Officer/Unit Head on increasing organizational effectiveness in these Units within Japan but across U.S. headquarters and other countries such as China, South Korea, and Taiwan. She has also worked in education, ISO certification, and at a foreign-affiliated human resource development in training program and sales roles—in both Japan and the U.S., utilizing her experience gained in Scotland and Canada. She joined GHIT Fund in 2019.
Miho Takazawa is Director of Finance & Operations at the GHIT Fund. Previously, she was Finance Manager in charge of Corporate/Special Purpose Company (SPC) Accounting and Treasury at Mapletree Investments Japan K.K., a Singaporean Real Estate Investment/Asset Management Company based in Japan. Prior to that she served in the Accounting Department at Fuji Bank/Mizuho Corporate Bank (now Mizuho Bank) in New York City. She holds an MBA and a BS in International Business from Southern New Hampshire University in the United States and a BA in the History of Chinese Thought from Atomi University in Japan.
Bumpei Tamamura is Senior Director of Brand Communications. Previously, he worked as a strategic planner at a communication agency and social marketing venture. He supported a wide range of clients from international organizations, government ministries, universities, research institutions, and pharmaceutical companies. Mr. Tamamura graduated from the Tokyo University of Pharmacy and Life Sciences, and received his MPH from Boston University School of Public Health.
Hayato Urabe is Director of Investment Strategy and Management at the GHIT Fund, where he oversees all portfolio management activities. Previously, Dr. Urabe held several positions across the energy, life sciences, and water treatment sectors, focusing on strategy planning, start-up due diligence, and project management in Silicon Valley. He was also a consultant at Synthetic Genomics for technologies ranging from nutrigenomics to biofuels. Dr. Urabe completed his Bachelor of Science in Molecular Biology, Master of Science in Innovation Management and Entrepreneurship Engineering, and Doctor of Philosophy in Biomedical Engineering from Brown University. In addition, Dr. Urabe earned as Master’s degree from the School of Global Policy and Strategy at University of California, San Diego.